RAREUltragenyx Pharmaceutical Inc
Smart Score
How it is scored →The Smart Score (1–10) describes how this instrument compares with its peers on published, rules-based measures of value, quality, trend, stability and dividend safety. It is not a forecast and not personal advice.
Compared with: Health care companies in USA (n = 211)
Current rating first published: · last recomputed · rating log
Factor scores
Percentiles within the peer group (100 = the best of its peers); dividend safety in points.
Main drivers
- 12-month trend (ex last month)weighs on the score · percentile 3
- Volatility (1 y)weighs on the score · percentile 7
- Return on assetsweighs on the score · percentile 7
Red flags and notes
- Serious warning:Heavy dilution Share count growing more than 10 % a year over three years.
- Serious warning:Financial distress Altman Z in the distress zone and negative free cash flow.
- Caution:Cash burn Negative free cash flow in at least two of the last three years.
- Caution:Negative equity Book equity is below zero.
Price chart
Interactive chart by TradingView: exchange prices are delayed, crypto and currencies are live.
Key metrics
Valuation
- P/S
- 2.0
- Free-cash-flow yield
- −33.3%
- Market cap (EUR)
- €1.3B
Dividends
- Dividend yield
- 0.00%
- Years of dividend growth
- 0
Returns and risk
- 1 day
- −0.1%
- 1 month
- +9.5%
- 1 year
- −53.0%
- Volatility, 1 yr
- 96.2%
- Max drawdown, 1 yr
- −64.8%
- Beta
- 1.25
Ratios from SEC filings and end-of-day prices; returns are price changes without dividends.
News and filings
- Ultragenyx Pharmaceutical Inc.: 8-K — Material agreement
FactSEC EDGAR · Filing · 14 Oct 2026
- Ultragenyx Pharmaceutical Inc.: 8-K — Material agreement
FactSEC EDGAR · Filing · 7 Oct 2026
- Ultragenyx Pharmaceutical Inc.: 8-K — Other events
FactSEC EDGAR · Filing · 17 Sep 2026
- Ultragenyx Pharmaceutical Inc.: 8-K — Other events
FactSEC EDGAR · Filing · 3 Sep 2026
- Ultragenyx Pharmaceutical Inc.: 8-K — Other events
FactSEC EDGAR · Filing · 20 Aug 2026
- Ultragenyx Pharmaceutical Inc.: 8-K — Other events
FactSEC EDGAR · Filing · 11 Aug 2026
- Ultragenyx Pharmaceutical Inc.: 10-Q — Quarterly report for the period ending 2026-06-30
FactSEC EDGAR · Filing · 5 Aug 2026
- Ultragenyx Pharmaceutical Inc.: 8-K — Results of operations
FactSEC EDGAR · Filing · 5 Aug 2026
- FactA filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.
- Media reportA headline from a named media outlet. We link to it and do not check it.
- RumourUnconfirmed: the headline itself hedges (“reportedly”, “sources say”, “in talks”), names no publisher, or comes from a news aggregator or an automated republisher.
Source: Filings: U.S. SEC EDGAR. The tone is scored automatically from the headline and can be wrong.
Score changes in the last 12 months
Every published rating and change, logged when it was published (EU Market Abuse Regulation).
| Date | Event | Balanced | Growth · Income | Warnings | Price at publication |
|---|---|---|---|---|---|
| First rating | 1/10 | 1 · — | Serious warning:Heavy dilutionSerious warning:Financial distressCaution:Cash burnCaution:Negative equity | Available with Invest Pro |
Ratings are rules-based descriptions, valid until the next scoring run (about 06:20 and 21:50 UTC) and the same for every visitor.
Withdraw from contract here · EU consumers: 14 days to withdraw from a purchase.